A practical reference on Melanotan II: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-06 and is reviewed periodically as new material appears.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Cyclic heptapeptide, C-terminally amidated |
| Approximate molecular mass | 1024 Da | Monoisotopic mass of the free peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Soluble in water and polar solvents | Also dissolves in neutral aqueous buffer |
| Common synonyms | Melanotan II, MT-II, MT-2 | Described as a melanocortin agonist in early literature |
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
ATP + H2O + oligopeptide [oligopeptide - binding protein][side 1] = ADP + phosphate + oligopeptide [side 2] + [oligopeptide - binding protein][side 1] 7.4.2.7 ABC-type alpha-factor-pheromone transporter The enzyme appears in viruses and cellular organisms characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. Does not undergo phosphorylation during the transport process. A yeast enzyme that exports the α-factor sex pheromone. ATP + H2O + alpha factor [side 1] = ADP + phosphate + alpha factor [side 2] 7.4.2.8 ABC-type protein-secreting ATPase The expected taxonomic range for this enzyme is: Archaea, Bacteria. A non-phosphorylated, non-ABC (ATP-binding cassette) ATPase that is involved in protein transport. ATP + H2O + cellular protein [side 1] = ADP + phosphate + cellular protein [side 2] 7.4.2.9 ABC-type dipeptide transporter The enzyme appears in viruses and cellular organisms. ATP-binding cassette (ABC) type transporter, characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the uptake of dipeptides and tripeptides.
=== Regional politics === Calabrian politics was strained by debates on the regional entity and choice of capital, partly over the implied job opportunities in the public and clerical sectors. In 1963, in the first Moro government, ministers and undersecretaries from Reggio Calabria and Catanzaro were excluded from the executive: the only Calabrians with appointments were Socialist Giacomo Mancini (Minister of Health) and Christian Democrat Riccardo Misasi (Ministries of Grace and Justice), both from Cosenza. On 21 March 1968, the Reggio Calabria City Council voted on an agenda that advocated for it to become the regional capital. To preserve city interests, the “Agitation Committee for the Defense of Reggio's Interests", headed by Christian Democrat lawyer Francesco Gangemi, was born. However, the 1970 law establishing Italian Regions confirmed the 1949 decision by which the Donatini-Molinaroli report determined that Catanzaro was the capital of the Calabria Region. This situation affected local and regional elections. Minor secular leftist parties (social democrats and republicans) elected their first representatives, mainly in Reggio and Cosenza. On 5 July 1970 Mayor Pietro Battaglia (CD) spoke in Piazza Duomo in front of 7,000 people. He proclaimed the city's right to be the regional capital. On 12 July, the prodrome of the uprising began in the city, with the creation of roadblocks and public demonstrations. That day, in Villa San Giovanni, Senate President Amintore Fanfani was challenged by the crowd.
== Clinical governance == In January 2024, Eucalyptus appointed former Australian deputy chief medical officer Nick Coatsworth as a clinical governance adviser following scrutiny over the prescribing of compounded semaglutide.
=== Added components === Individual nutrient components may be added to more precisely adjust the body contents of it. That individual nutrient may, if possible, be infused individually, or it may be injected into a bag of nutrient solution or intravenous fluids (volume expander solution) that is given to the patient. Administration of individual components may be more hazardous than administration of pre-mixed solutions such as those used in total parenteral nutrition, because the latter are generally already balanced in regard to e.g. osmolarity and ability to infuse peripherally. Incorrect IV administration of concentrated potassium can be lethal, but this is not a danger if the potassium is mixed in TPN solution and diluted. Vitamins may be added to a bulk premixed nutrient immediately before administration, since the additional vitamins can promote spoilage of stored product. Vitamins can be added in two doses, one fat-soluble, the other water-soluble. There are also single-dose preparations with both fat- and water-soluble vitamins such as Cernevit. Minerals and trace elements for parenteral nutrition are available in prepared mixtures, such as Addaven. These additional components in parenteral nutritions, however were subject to stability checks, since they greatly affect the stability of lipid emulsions that serve as the base for these formulations. Studies have shown differences in physical and chemical stabilities of these total parenteral nutrition solutions, which greatly influences pharmaceutical manufacturing of these admixtures.
== External links == ImmPort - Gene summaries, ontologies, pathways, protein/protein interactions and more for genes involved in antigen processing and presentation antigen+presentation at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
=== Medical treatments === Palovarotene (Sohonos) was approved for medical use in the United States in 2023. Palovarotene is a highly selective retinoic acid receptor gamma (RARγ) agonist that has been shown to reduce the volume of new heterotopic ossification in people (males >10 years, females >8 years). Garetosmab (Pasatru) was approved for medical use in the United States in August 2026. Zilurgisertib (Atebrioz) was approved for medical use in the United States in September 2026.
The wavelength of the UV light for the lower TOC waters must be less than 200 nm and is typically 184 nm generated by a low pressure Hg vapor lamp. The 184 nm UV light is energetic enough to break the water molecule into OH and H radicals. The hydrogen radicals quickly react to create H2. The equations follow: H2O + hν (185 nm) → OH• + H • and H • + H • → H2 Different types of UPW TOC Analyzers IC (Inorganic Carbon) = CO2 + HCO−3 + CO2−3 TC (Total Carbon) = Organic Carbon + IC TOC (Total Organic Carbon) = TC – IC H2O + hν (185 nm) → OH• + H • S2O2−8 + hν (254 nm) → 2 SO−4 • SO−4 • + H2O → HSO−4 + OH •
== External links == National Isotope Development Center U.S. Government resources for isotopes - production, distribution, and information Isotope Development & Production for Research and Applications (IDPRA) U.S. Department of Energy program sponsoring isotope production and production research and development
=== Detection === A procedure of retrospective detection of Novichok type poisons in victim's tissues was proposed in 2021-2. This method is a modification of the procedure that was developed earlier for identification of sarin poisoning. This method capitalizes on the fact that poisoning by organic phosphonates occurs via phosphonylation of the hydroxy group of serine in the active site of cholinesterases, and that severe poisoning occurs when a major part of these enzymes are inactivated. The concentration of butyryl cholinesterase (HuBuChE) in human plasma is normally about 80 nM. That makes it a good source of adducts that can be subjected to analysis. The procedure consists of three steps (see the Figure A). First, HuBuChE is obtained from the victim's plasma. Second, the enzyme is subjected to pepsin proteolysis. Third, the peptide mixture obtained is subjected to LC-MSMS analysis. If no poisoning took place, the peptide mixture contains a non-modified nonapeptide FGESAGAAS. However, cholinesterases are inactivated due to a chemical reaction with Novichok type nerve agent, the modified nonapeptide is be detected, and its exact (high resolution) mass (along with the mass of the secondary ion produced during collision induced dissociation) allows unambiguous identification of the fact of poisoning and the exact structure of the poison. Thus, the example at Figure A shows the masses of the primary and secondary ions obtained from the plasma of the victim poisoned by A-230. If a victim is poisoned by other Novichok type agents, the masses are different.
Sources: en.wikipedia.org
No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.
Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.
Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.